Safety and Efficacy of Lorbrena

Back to Search
Print
Bookmark Trial

NCT03844464

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
3-22-7, Yoyogi, Shibuya-ku
Tokyo, , 151-8589, Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All administered patients

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Nothing

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Non-Small Cell Lung CancerStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
NCT02920450
  1. Gainesville, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerEffect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
NCT00300729
  1. Gothenburg,
  2. Jönköping,
  3. Kalmar,
  4. Linköping,
  5. Lund,
  6. Malmö,
  7. Skövde,
  8. Trollhättan,
  9. Uddevalla,
  10. Umeå,
  11. Uppsala,
  12. Ystad,
  13. Örebro,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerA Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00555256
  1. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
NCT03915951
  1. Los Angeles, California
  2. Santa Monica, California
  3. Norwich, Connecticut
  4. Putnam, Connecticut
  5. Lady Lake, Florida
  6. Venice, Florida
  7. Overland Park, Kansas
  8. Baltimore, Maryland
  9. Baltimore, Maryland
  10. Boston, Massachusetts
  11. Boston, Massachusetts
  12. Boston, Massachusetts
  13. Boston, Massachusetts
  14. Boston, Massachusetts
  15. Chelsea, Massachusetts
  16. Danvers, Massachusetts
  17. Marlborough, Massachusetts
  18. Stoneham, Massachusetts
  19. Waltham, Massachusetts
  20. Independence, Missouri
  21. Independence, Missouri
  22. Kansas City, Missouri
  23. Kansas City, Missouri
  24. Basking Ridge, New Jersey
  25. Montvale, New Jersey
  26. Bronx, New York
  27. Bronx, New York
  28. New York, New York
  29. New York, New York
  30. New York, New York
  31. Columbus, Ohio
  32. Clackamas, Oregon
  33. Newberg, Oregon
  34. Portland, Oregon
  35. Pittsburgh, Pennsylvania
  36. Pittsburgh, Pennsylvania
  37. Pittsburgh, Pennsylvania
  38. Pittsburgh, Pennsylvania
  39. York, Pennsylvania
  40. Chattanooga, Tennessee
  41. Hendersonville, Tennessee
  42. Houston, Texas
  43. Shenandoah, Texas
  44. Faenza, Emilia-romagna
  45. Lugo, Emilia-romagna
  46. Ravenna, Emilia-romagna
  47. Rimini, Emilia-romagna
  48. Milano, Lombardia
  49. Torino, Piemonte
  50. Cattolica, Rimini
  51. Orbassano, Torino
  52. Milano,
  53. Naples,
  54. Amsterdam, Noord-holland
  55. Hospitalet de Llobregat, Barcelona
  56. L'Hospitalet de Llobregat, Barcelona
  57. L'Hospitalet de Llobregat, Barcelona
  58. L'Hospitalet de Llobregat, Barcelona
  59. Barcelona,
  60. Barcelona,
  61. Hospitalet de Llobregat,
  62. Sevilla,
  63. Norwich, Connecticut
  64. Fort Myers, Florida
  65. Saint Petersburg, Florida
  66. Tallahassee, Florida
  67. Atlanta, Georgia
  68. Baltimore, Maryland
  69. Boston, Massachusetts
  70. Boston, Massachusetts
  71. Boston, Massachusetts
  72. Stoneham, Massachusetts
  73. Saint Louis, Missouri
  74. Hackensack, New Jersey
  75. Bronx, New York
  76. New York, New York
  77. New York, New York
  78. Durham, North Carolina
  79. Columbus, Ohio
  80. Portland, Oregon
  81. York, Pennsylvania
  82. Chattanooga, Tennessee
  83. Nashville, Tennessee
  84. Houston, Texas
  85. Seattle, Washington
  86. Ravenna, Emilia-romagna
  87. Milano, Lombardia
  88. Napoli, Naples
  89. Bologna,
  90. Goyang-si, Gyeonggido
  91. Jeonnam,
  92. Seoul,
  93. Seoul,
  94. Seoul,
  95. Amsterdam, Noord-holland
  96. Groningen,
  97. Majadahonda, Madrid
  98. Malaga, Málaga
  99. Barcelona,
  100. Barcelona,
  101. Barcelona,
  102. Córdoba,
  103. Madrid,
  104. Madrid,
  105. Sevilla,
  106. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Safety and Efficacy of Lorbrena
Official Title Special Investigation for LORBRENA Tablets
Brief Summary

To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug

  1. Factors affecting the onset of central nervous system disorder
  2. Effect of Lorbrena in combination with CYP3A inducers on the onset of hepatic dysfunction
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population 651 patients
Condition Non-small Cell Lung Cancer
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: February 15, 2019)		651
Original Estimated Enrollment Same as current
Estimated Study Completion Date August 11, 2023
Estimated Primary Completion Date August 11, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • All administered patients

Exclusion Criteria:

  • Nothing
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries Japan
Removed Location Countries  
 
Administrative Information
NCT Number NCT03844464
Other Study ID Numbers B7461018
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2020